Logo-bi
Editorial

1. Personalized cell-mediated immunotherapy and vaccination: combating detrimental uprisings of malignancies
Jaleh Barar* ORCID, Yadollah Omidi* ORCID
Bioimpacts. 2015;5(2): 65-69. doi: 10.15171/bi.2015.18
PMCID: PMC4492186     PMID: 26191499     Scopus ID: 84930410369    
Article
PDF
XML
Cited By:
3
0
2
Perspective

2. A prospective highlight on exosomal nanoshuttles and cancer immunotherapy and vaccination
Mohammad A. Rafi, Yadollah Omidi* ORCID
Bioimpacts. 2015;5(3): 117-122. doi: 10.15171/bi.2015.22
PMCID: PMC4597158     PMID: 26457248     Scopus ID: 84944384880    
Article
PDF
XML
Cited By:
16
5
15
Review

3. Pleiotropic cytotoxicity of VacA toxin in host cells and its impact on immunotherapy
Farnaz Fahimi, Mohammad Reza Tohidkia, Mehdi Fouladi, Reza Aghabeygi, Naser Samadi, Yadollah Omidi* ORCID
Bioimpacts. 2017;7(1): 59-71. doi: 10.15171/bi.2017.08
PMCID: PMC5439391     PMID: 28546954     Scopus ID: 85019068034    
Article
PDF
Full Text
XML
Cited By:
19
9
18
Editorial

4. Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities
Nastran Hashemzadeh, Khosro Adibkia ORCID, Jaleh Barar* ORCID
Bioimpacts. 2019;9(1): 1-3. doi: 10.15171/bi.2019.01
PMCID: PMC6378097     PMID: 30788254     Scopus ID: 85060480524    
Article
PDF
Full Text
XML
Cited By:
6
0
5
Original Research

5. Silibinin induces immunogenic cell death in cancer cells and enhances the induced immunogenicity by chemotherapy

Sevda Jafari ORCID, Saba Heydarian, Raymond Lai, Elnaz Mehdizadeh Aghdam, Ommoleila Molavi* ORCID
Bioimpacts. 2023;13(1): 51-61. doi: 10.34172/bi.2022.23698
PMCID: PMC9923812     PMID: 36816998     Scopus ID: 85152099837    
Article
PDF
Suppl 1
Full Text
XML
Cited By:
14
2
14
Evaluation of different variables on preparation of Microspheres. F9; Freeze-dried particles prepared by W/O/W emulsion method, F1; Dried particles on the tray at room temperature, F16; Freeze-dried particles prepared by S/O/O emulsion method. W/O/W; Water in oil in water, S/O/O; Solid in oil in oil.
Review

6. Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands
Leila Rostamizadeh ORCID, Ommoleila Molavi* ORCID, Mohsen Rashid, Fatemeh Ramazani, Behzad Baradaran, Afsaneh Lavasanaifar, Raymond Lai
BioImpacts. 2022;12(3): 261-290. doi: 10.34172/bi.2022.23896
PMCID: PMC9124882     PMID: 35677663     Scopus ID: 85132074584    
Article
PDF
Full Text
XML
Cited By:
16
5
4
In this paper, we will review the application of the four most widely studied TLR agonists including agonists of TLR3, 4, 7, and 9 in cancer immunotherapy.
Original Article

7. Modulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer
Xiuying Li* ORCID, Xianqin Luo, Shunqin Hu
Bioimpacts. 2023;13(2): 89-96. doi: 10.34172/bi.2023.24166
PMCID: PMC10182444     PMID: 37193073     Scopus ID: 85152093865    
Article
PDF
Full Text
XML
Cited By:
1
0
0
Our results indicated that losartan can modulate the tumor microenvironment, and improve the efficacy of anti-PD-L1 mAb.
Review

8. The application, safety, and future of ex vivo immune cell therapies and prognosis in different malignancies
Katelyn R. Einloth ORCID, Scott Gayfield, Thomas McMaster, Alexander Didier, Lance Dworkin, Justin Fortune Creeden* ORCID
Bioimpacts. 2023;13(6): 439-455. doi: 10.34172/bi.2023.27521
PMCID: PMC10676524     PMID: 38022382     Scopus ID: 85172806877    
Article
PDF
Full Text
XML
Cited By:
1
0
1
Original Article

9. Cytotoxicity of WT1-reactive T cells against Wilms tumor: An implication for antigen-specific adoptive immunotherapy
Seyed Mostafa Monzavi ORCID, Amir Ali Hamidieh ORCID, Mohammad Vasei, Jafar Ai, Naser Ahmadbeigi, Hamid Arshadi, Samad Muhammadnejad* ORCID, Abdol-Mohammad Kajbafzadeh* ORCID
Bioimpacts. 2023;13(5): 415-424. doi: 10.34172/bi.2023.27576
PMCID: PMC10509739     PMID: 37736339     Scopus ID: 85172764297    
Article
PDF
Full Text
XML
Cited By:
1
0
1
Original Article

10. Introduction of a new recombinant vaccine based on GRP78 for breast cancer immunotherapy and evaluation in a mouse model
Hamed Zare ORCID, Hamid Bakherad* ORCID, Arman Nasr Esfahani, Mohamad Norouzi, Hossein Aghamollaei, Seyed Latif Mousavi Gargari, Fatemeh Mahmoodi, Mahdi Aliomrani, Walead Ebrahimizadeh
Bioimpacts. 2024;14(2): 27829. doi: 10.34172/bi.2023.27829
PMCID: PMC10945302     PMID: 38505675     Scopus ID: 85175869724    
Article
PDF
XML
Cited By:
3
0
2
Review

11. CRISPR-Cas9 in basic and translational aspects of cancer therapy
Maryam Samareh Salavatipour ORCID, Zahra Poursalehi, Negin Hosseini Rouzbahani, Sohaib Mohammadyar, Mohammad Vasei* ORCID
Bioimpacts. 2024;14(6): 30087. doi: 10.34172/bi.2024.30087
PMCID: PMC11530967     PMID: 39493894     Scopus ID: 85209235663    
Article
PDF
XML
Cited By:
0
0
0

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge